Quin Wills (L) and Jack O’Meara
A UK biotech looks to upset the preclinical model for liver drug development, and now it's gearing up for the clinic
Liver disease is one of the hardest therapeutic areas to hit, and some researchers have pointed to a dearth of meaningful preclinical models during drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
